Related Experiment Video

Updated: Aug 15, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis

H W Murray1

  • 1Division of Infectious Diseases, Cornell University Medical College, New York, New York.

The Journal of Infectious Diseases
|May 1, 1990
PubMed

Insights

Continuous delivery of interferon-gamma (IFN-gamma) significantly enhanced its antileishmanial effects in mice. This optimized immunotherapy, alone or with chemotherapy, offers a promising strategy for treating visceral leishmaniasis.

Area of Science:

  • Immunology
  • Parasitology
  • Pharmacology

Background:

  • Interferon-gamma (IFN-gamma) shows antileishmanial activity.
  • Current intermittent delivery methods yield primarily microbistatic effects.

Purpose of the Study:

  • To investigate if continuous IFN-gamma delivery enhances efficacy against visceral leishmaniasis.
  • To compare continuous vs. intermittent IFN-gamma delivery.
  • To assess combined continuous IFN-gamma and antimony therapy.

Main Methods:

  • Visceral leishmaniasis model in mice infected with Leishmania donovani.
  • Subcutaneous osmotic pumps for continuous IFN-gamma administration.
  • Comparison with once-daily intraperitoneal injections.
  • Evaluation of liver parasite burdens and combined therapy effects.

Main Results:

  • Continuous IFN-gamma (2.4 x 10^5 units/day) reduced liver parasite burdens by nearly 50%.
  • Intermittent IFN-gamma injections showed limited impact on overall parasite load.
  • Continuous IFN-gamma plus antimony demonstrated an additive antileishmanial effect.

Conclusions:

  • Continuous delivery of IFN-gamma optimizes in vivo antimicrobial effects.
  • Macrophage-activating lymphokines may require continuous infusion for maximal efficacy.
  • This approach holds potential for improved visceral leishmaniasis treatment.

More Related Videos

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase05:55

In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase

Published on: April 4, 2025

Related Concept Videos

Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...